Pfizer / BioNtech recommends a third dose of its vaccine to increase its effectiveness at a time when the highly contagious Delta variant is causing epidemic outbreaks in Asia and Africa and is pushing up the number of cases in Europe and the United States.
Six months after the 2nd dose
The Pfizer / BioNTech alliance has announced plans to request “in the coming weeks” authorization for a third dose of its vaccine against Covid-19, in the United States and in Europe in particular.
“Preliminary study data show that a booster dose given 6 months after the second dose has a consistent safety profile, while eliciting high levels of neutralizing antibodies” against the virus, including against the Beta variant , appeared in South Africa.
These levels are “5 to 10 times higher” than those seen after the initial two doses.
The two companies also pointed out that their vaccine had shown good results in the laboratory against the Delta variant, and that a third dose would therefore be able to boost immunity against it as well. Tests are underway to “confirm this hypothesis,” they said.